What is the effect of anti-thrombotic therapy on stroke prevention in AF?
In a meta-analysis of 2,900 subjects from 6 randomized trials, adjusted-dose warfarin was associated with a 64% relative risk reduction in stroke (95% CI, 49-74). In a meta-analysis of 8 trials of 4,876 subjects, APT compared with control or placebo was associated with a 22% (95% CI, 6-35) relative risk reduction in stroke. The Stroke Prevention in AF (SPAF-I) study demonstrated decrease in risk of stroke from 6.3% per year in placebo subjects to 3.6% per year but a meta-analysis of 7 trials of 3,990 subjects found no significant benefit.